If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...

进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

REC-994是Recursion立项最早的项目之一，一度也是进度最靠前的临床管线，并且在Ⅱ期研究中，展现出病灶缩小、功能改善的积极信号，但在后续的长期扩展研究中，这种疗效未能维持，转换剂量组也没有积极趋势。

加利福尼亚州门洛帕克 - PacBio (NASDAQ:PACB)今日发布新闻稿宣布,任命Christopher Gibson博士加入其董事会。 Gibson是临床阶段生物技术公司Recursion (NASDAQ:RXRX)的联合创始人兼董事会主席。在Recursion,他领导开发了一个将生物数据生成与机器学习相结合的药物发现平台。他带领公司完成了募集资金、战略合作伙伴关系建立以及公开上市。 P ...

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Artificial intelligence (AI) is all the rage on Wall Street these days, but not every AI stock is equally successful. Some of ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

英为财情Investing.com - Recursion Pharmaceuticals (NASDAQ: RXRX )星期三发布了第四季度的财报，数据显示，公司营收高于分析师的预期，每股收益超出了分析师的预期。

Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.